US seeks new dawn for paediatric devices R&D
This article was originally published in RAJ Devices
The US industry has welcomed initiatives by the Senate Health, Education, Labor and Pensions Committee to promote the development of new treatments for rare paediatric diseases. A HELP Committee hearing, held on 21 July, featured an acknowledgement of the gap that devices can help fill in the current unmet needs1.
You may also be interested in...
Biologic Exclusivity Provisions In USMCA Are Boon To Generics Industry; BIO Is 'Tremendously Worried'
Revised North American trade deal touted as enabling Congress to address crisis of high drug prices; requirement for 10 years biologic exclusivity is removed and language to allow incentives for generics added.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.